NCT06300892

Brief Summary

This is a prospective, observational study of patients undergoing open GI surgery. At the time of operation, samples will be collected from the incision site and GI tract. The study will follow patients up to 30 days postoperatively, monitoring for signs of SSI. Samples will be taken from all patients who develop SSI. Sequencing will be performed on a subset of samples based on our specific aims.

  • Aim 1: conduct a case-control study of patients with SSI and age-, sex-, diagnosis-, and wound class-matched control patients without SSI, comparing microbiome alpha diversity and community composition with 16S RNA sequencing to determine the association with SSI.
  • Aim 2: identify the strain of bacteria isolated from SSIs using shotgun metagenomic sequencing and determine whether the specific strain was present in the skin and gut at the time of operation.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
1mo left

Started Apr 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Apr 2024Jul 2026

First Submitted

Initial submission to the registry

March 1, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 8, 2024

Completed
24 days until next milestone

Study Start

First participant enrolled

April 1, 2024

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 15, 2026

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2026

Expected
Last Updated

May 26, 2026

Status Verified

May 1, 2026

Enrollment Period

2.2 years

First QC Date

March 1, 2024

Last Update Submit

May 22, 2026

Conditions

Outcome Measures

Primary Outcomes (3)

  • alpha diversity composition

    Alpha diversity composition at the surgical incision site at multiple time points

    Baseline, Day 30 post-op

  • microbial community composition

    microbial community composition at the surgical incision site at multiple time points

    Baseline, Day 30 post-op

  • pathogenic strain of bacteria

    Pathogenic strain of bacteria at SSI compared with pathogens isolated from skin and/or GI tract microbiome

    Baseline, Day 30 post-op

Study Arms (2)

Patients undergoing open GI surgery

Patients with SSI

Other: No intervention

Control group

age-, sex-, diagnosis-, and wound class-matched control patients without SSI

Other: No intervention

Interventions

samples from the incision site and GI tract collected

Control groupPatients undergoing open GI surgery

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

adults over the age of 18 years, who are undergoing open abdominal surgery with a midline incision.

You may qualify if:

  • We will include adult patients (age ≥ 18 years)
  • Undergoing open abdominal surgery during the study period.
  • Open abdominal surgery will include any abdominal procedure entering the peritoneal cavity through a midline incision with a skin incision that is 5cm or greater.

You may not qualify if:

  • Patients with planned minimally invasive surgery including laparoscopic or robotic surgery as these patients have lower rates of surgical site infections (SSIs). Patients who have a laparoscopic or robotic surgery converted to open surgery will be excluded.
  • Appendectomy and cholecystectomy as these patients have lower risk of SSI.
  • Vascular, gynecological, obstetric, urological or transplantation.
  • Trauma patients.
  • Patients without source control at the index operation including those with an open abdomen, no fascial closure, or temporary abdominal closure device (such as abthera dressing).
  • Pediatric patients (age\<18 years).
  • Patients who decline swab/specimen collection.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Minnesota

Minneapolis, Minnesota, 55414, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

samples from the incision site and GI tract

Study Officials

  • Jennifer Rickard

    University of Minnesota

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kathryn Vera

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 1, 2024

First Posted

March 8, 2024

Study Start

April 1, 2024

Primary Completion

June 15, 2026

Study Completion (Estimated)

July 30, 2026

Last Updated

May 26, 2026

Record last verified: 2026-05

Locations